To spur sales of its poorly selling Alzheimer’s drug, Biogen is cutting the price in half to $28,200 a year per patient
Biogen Inc. is slashing in half the price of its controversial new Alzheimer’s disease treatment, Aduhelm, in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.
when the drug was approved in June, Biogen said Monday.Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Strictly fans say Glitterball trophy should be cut in half after closest finalAfter a super close and emotional final of Strictly Come Dancing, viewers watching at home called for the coveted Glitterball trophy to be shared between the four worthy finalists
Read more »
How To Structure A Permanent Child Tax Credit ExpansionDemocrats must get creative if they want to preserve this critical accomplishment, which helped cut child poverty in half this year.
Read more »
Researchers look to once-taboo frontier — psychedelics — to treat 'anguished' health workersIn a first-of-its kind clinical trial, a research team will treat 30 depressed medical professionals with a dose of synthetic psilocybin — a psychedelic drug — to see if the drug, along with psychotherapy, can reduce their mental anguish.
Read more »
A3 charter school fraud defendant sentenced to probation, fined $300,000Robert Williams cooperated with prosecutors and paid half of his fines at sentencing Friday, prosecutor said.
Read more »
19 Badass Pixie Cuts That Make Me Want to Cut My Hair OffLooks like I'm going to the salon today.
Read more »